Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 8 July 2026 to Question 12794, how the commitment made in the Written Statement of 2 June 2026 to maintain and regularly update the UK National Screening Committee's prostate cancer screening model as new evidence becomes available will operate in practice; and when the Committee expects to assess the recently published evidence on the Stockholm3 test.

Despite some recent misinformed media coverage, I can confirm to the Hon. Members that there has been no change to the policy in respect of prostate specific antigen (PSA) testing for men aged over 50 years old. Any such man who is concerned about prostate cancer, regardless of whether they have symptoms, remains free to make an appointment with their general practitioner, raise their concerns, and ask for a PSA test, exactly as they have done in the past. No impact assessment was therefore made when the guidance in this area was consolidated and updated in June, as there was no change in policy to assess.

The two main studies from the Cochrane review were included in the UK National Screening Committee modelling when they made their most recent recommendation regarding prostate cancer screening, and it should be noted that the Cochrane review came to the same statistical conclusions as the UK National Screening Committee regarding ‘mortality reduction", sometimes called lives saved, from PSA testing and subsequent treatment.

With regard to the next review of prostate cancer screening, I refer the Hon. Members to the article published by the UK National Screening Committee on 11 August 2026, which is available at the following link:

https://nationalscreening.blog.gov.uk/2026/08/11/the-uk-nscs-prostate-cancer-screening-model-will-remain-open-and-under-review/